

LIFELINE THERAPEUTICS, INC.  
Form 8-K  
April 12, 2005

**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934

Date of Report: April 11, 2005

**LIFELINE THERAPEUTICS, INC.**  
(Exact name of registrant as specified in its charter)

<b>Colorado</b>	<b>000-30489</b>	<b>84-1097796</b>
_____ (State or other jurisdiction of incorporation)	_____ (Commission File Number)	_____ (IRS Employer Identification Number)

6400 South Fiddler's Green Circle, Suite 1750, Englewood, CO 80111  
(New address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (720) 488-1711

YAAK RIVER RESOURCES, INC.  
(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 

**Section 1 Registrant's Business and Operations**

**Item 1.01 Entry into a Material Definitive Agreement**

None

**Item 1.02 Termination of a Material Definitive Agreement**

None

**Item 1.03 Bankruptcy or Receivership**

None

**Section 2 Financial Information**

**Item 2.01 Completion of Acquisition or Disposition of Assets**

None

**Item 2.02 Results of Operations and Financial Condition**

None

**Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant**

None

**Item 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement**

None

**Item 2.05 Costs Associated with Exit or Disposal Activities**

None

**Item 2.06 Material Impairments**

None

**Section 3 Securities Trading Markets**

**Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing**

None

2

---

**Item 3.02 - Unregistered Sales of Equity Securities**

None

**Item 3.03 Material Modification to Rights of Security Holders**

None

**Section 4 - Matters Related to Accountants and Financial Statements**

**Item 4.01 Changes in Registrant's Certifying Accountants**

None

**Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review**

None.

**Section 5 - Corporate Governance and Management**

**Item 5.01 Changes in Control of Registrant**

None

**Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers**

On April 6, 2005, the Board of Directors appointed Dr. James D. Crapo as a member of the Board of Directors. Dr. Crapo brings nearly 30 years of experience in the health and science field to his new role. He served as the Chairman of Medicine at the National Jewish Medical and Research Center, from 1996, until his recent sabbatical in 2004.

National Jewish is a top-rated private institution in immunology and allergic diseases and has been rated number one nationally in pulmonary medicine by *U.S. News and World Report* for the past 7 years. Dr. Crapo maintains a large research program focused on the role of oxidants and anti-oxidants in the causation and treatment of diseases. He was the first scientist to extend Dr. Fridovich and Dr. McCord's (Director of Science for Lifeline Therapeutics) original discovery of SOD to mammalian models of disease. SOD is the body's most powerful natural antioxidant.

3

---

Prior to coming to National Jewish, Dr. Crapo spent over 15 years as the Chief of the Pulmonary and Critical Care Medicine Division at Duke University Medical Center. Throughout his professional career he has been active in numerous professional societies, including service on the NHLBI Advisory Council and serving as President of the American Thoracic Society and President of the Fleischner Society. Dr. Crapo has authored more than 200 original scientific publications, numerous book chapters and seven textbooks.

**Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year**

None

**Item 5.04 Temporary Suspension of Trading Under Registrant's Employee Benefit Plans**

None

**Item 5.05 Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics.**

None

**Section 6 [Reserved]**

**Section 7 - Regulation FD**

**Item 7.01 Regulation FD Disclosure**

None

**Section 8 - Other Events**

**Item 8.01 Other Events**

None

**Section 9 - Financial Statements and Exhibits**

**Item 9.01 Financial Statements and Exhibits**

- (a) Financial Statements of Businesses Acquired.
- (b) Pro Forma financial information.
- (c) Exhibits

4

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: April 11, 2005

LIFELINE THERAPEUTICS, INC.

By: /s/ Daniel W. Streets  
Daniel W. Streets, CFO/Secretary

5

---